ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
NHS England reaches deal with Gilead on CAR-T therapy Yescarta
October 09, 2018National Health Service (NHS) England has reached an agreement with Gilead Sciences to provide the pharmaceutical company’s chimeric antigen receptor T-cell (CAR-T) therapy Yescarta (axicabtagene ciloleucel) for adults with large cell lymphoma. -
Gilead's CAR-T cell therapy Yescarta gains EU clearance; meets first resistance from NICE
August 29, 2018Gilead Sciences' Kite unit announced that the European Commission approved Yescarta (axicabtagene ciloleucel) as a treatment for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL) -
Gilead could make a move for Galapagos within weeks
December 18, 2017The share price of Belgium-Dutch biotech Galapagos is rising thanks to renewed speculation that Gilead may be poised to acquire it. -
FDA approves Yescarta to treat adults with B-cell lymphoma
October 20, 2017The FDA has approved Yescarta, a cell-based gene therapy, to treat adult patients with certain types of large B-cell lymphoma…
Pharma Sources Insight January 2025
